Ichiza lokuQala eliLungisiweyo eliDibeneyo lokuQalwa kuHlobo lweSifo seswekile

IGlenmark Pharmaceuticals Limited iqalise inoveli indibaniselwano yedosi emiselweyo (FDC) ye-DPP4 inhibitor esetyenziswa ngokubanzi (i-Dipeptidyl Peptidase 4 inhibitor), iTeneligliptin, kunye nePioglitazone. Le yodwa i-DPP4 ekhoyo kunye ne-Glitazone yokudibanisa i-brand e-Indiya kubantu abadala abane-Type ye-2 yeswekile engalawulwayo. UGlenmark uphehlelele le FDC phantsi kwegama lebrendi iZita Plus Pio, equlethe iTeneligliptin (20 mg) + nePioglitazone (15 mg), ekufuneka ithathwe kanye ngemini.

Ukuphawula malunga nophuhliso, u-Alok Malik, i-Vice-President yeQela kunye neNtloko, i-India Formulations - i-Glenmark Pharmaceuticals, yathi, "Isifo seswekile yindawo ephambili ekugxilwe kuyo eGlenmark; uvulindlela ekuboneleleni ngokufikelela kwiinketho zonyango zamva nje kwizigulane ezineswekile eIndiya. Kuyasivuyisa ukwazisa le noveli iZita Plus Pio, eyeyokuqala ngqa eIndiya; ibonelela ngonyango olukumgangatho wehlabathi nolufikelelekayo kubantu abadala abanesifo seswekile.”

IGlenmark yinkampani yokuqala e-Indiya ukuthengisa i-FDC entsha ye-Teneligliptin + Pioglitazone, evunywe yi-DCGI (uMlawuli Jikelele weZiyobisi waseIndiya). Le ndibaniselwano yedosi emiselweyo iya kuba luncedo kwizigulana ezifuna unyango nge-Teneliglitptin kunye ne-Pioglitazone (njengamachiza ahlukeneyo) ukuphucula ulawulo lwe-glycemic ekunciphiseni i-Insulin Resistance. 

Udidi lwesi-2 lweswekile luhlala lujongana nemiba yokungasebenzi kakuhle kweeseli ze-β kunye nokumelana ne-insulin. I-Glenmark's FDC ye-Teneligliptin + Pioglitazone inamandla okumelana nezi zimbini zibalulekileyo ze-pathophysiologies eyenza ukuba i-FDC isebenze ngakumbi ekulawulweni kwe-Type 2 yeswekile engalawulekiyo. Indibaniselwano yeTeneligliptin + Pioglitazone iya kubonelela ngendlela ehambelanayo apho iTeneligliptin iya kuphucula ngokugqibeleleyo uvakalelo lwe-β cell, kwaye iPioglitazone iyakunciphisa ngokusebenzayo ukuxhathisa kwe-insulin.

Igalelo likaGlenmark kunyango lwesifo seswekile

Ngo-2015, iGlenmark yatshintsha imarike yeswekile ngokusungula inhibitor yayo ye-DPP4-Teneligliptin eIndiya, ilandelwa yi-FDC yeTeneligliptin + Metformin. IGlenmark inelifa elomeleleyo elingaphezulu kwamashumi amane eminyaka yenkqubela phambili kunye nokusungula izinto ezintsha. Ukuqhubekeka ukuya kwixesha layo lokuqala kwilifa laseIndiya, iye yaphehlelela i-FDC yeTeneligliptin + Remogliflozin ngo-2021.

I-Indiya yaziwa ngokuba likomkhulu lesifo seswekile kwihlabathi. Ngokutsho kwe-International Diabetes Federation (IDF), ukuxhaphaka kwesifo seswekile eIndiya malunga ne-74 yezigidi zabantu abadala, okulindeleke ukuba kwandiswe kwi-125 yezigidi (phantse i-70% ukunyuka) ngo-2045 [i]. Kwaba, i-77% yezigulane zinesifo seswekile esingalawulwayo.